KAI1/CD82在神经母细胞瘤组织中的表达及其与预后的关系

背景与目的KAI1/CD82是近年来发现的肿瘤转移抑制基因,它的失活与某些肿瘤的进展和浸润有关。本研究旨在通过检测KAI1/CD82蛋白在神经母细胞瘤中的表达,探讨其与神经母细胞瘤临床病理特征和预后的关系。方法用免疫组化EnVision法检测90例神经母细胞瘤瘤组织中KAI1/CD82蛋白的表达,结合临床资料与随访资料进行统计学分析。结果39.3%(11/28)节细胞神经母细胞瘤KAI1/CD82呈阳性表达,14.5%(9/62)神经母细胞瘤KAI1/CD82呈阳性表达(P=0.014)。KAI1/CD82的表达与神经母细胞瘤的分化程度呈显著性正相关,且KAI1/CD82的表达与临床分期呈显著性负相关(P=0.003)。结论KAI1/CD82表达的改变是神经母细胞瘤发生的早期事件,其表达下调是神经母细胞瘤分化和转移的一个潜在标志。此标记物可能作为临床评估预后的综合指标之一。

Expression of KAI1/CD82 in neuroblastoma and its correlation to prognosis

BACKGROUND & OBJECTIVE: KAI1/CD82 was recently detected as a tumor metastasis suppressor gene. Its silencing contributes to progression and infiltration of some tumors. Our study was designed to investigate the expression of KAI1/CD82 in neuroblastoma, and explore its correlation to clinicopathologic characteristics and prognosis of patients with neuroblastoma. METHODS: The EnVisionTM immunohistochemistry was used to detect the expression of KAI1/CD82 in 90 specimens of neuroblastoma (28 specimens of ganglioneuroblastoma and 62 specimens of neuroblastoma). Clinical data and follow-up data of the 90 patients were analyzed. RESULTS: Positive rate of KAI1/CD82 was significantly higher in ganglioneuroblastoma than in neuroblastoma (39.3% vs. 14.5%, P=0.014). Its expression was negatively correlated to clinical stage of neuroblastoma (P=0.003). CONCLUSIONS: The change of KAI1/CD82 expression is an early event in tumorigenesis of neuroblastoma. Its down-regulation may be considered as a potential indicator to judge the differentiation and metastasis of neuroblastoma, which can serve as one of the combined indexes to clinical assessment of prognosis.